NCT01193491View on ClinicalTrials.gov

Dose Escalation of IPI-493 in Hematologic Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Hematologic Malignancies
Interventions
DRUG

IPI-493

Capsules, ascending dose, multiple schedules

Trial Locations (3)

10065

Weill Cornell Cancer Center, New York

21201

Johns Hopkins Sidney Kimmel Cancer Center, Baltimore

77030

M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY